Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...

With three nights in three months, "Art Of The Machine" will educate about Narcan use and honor the artwork on the machines.

For some people, going on vacation by plane is really no fun. The difference in pressure causes them enormous earaches. And ...

On Wednesday, the House Labor, Health and Social Services Committee voted unanimously in favor of Senate File 74, “ Immunity ...

Tears were shed Friday at the Hawaii Island Fentanyl Task Force sign-waving rally as former addicts, victims, anti-drug ...

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Milestone Pharmaceuticals (MIST) announced that it has received Notice of Allowance from the United States Patent and Trademark Office, or ...

Researchers at Texas A&M University College of Medicine have developed a new therapy that may slow the progression of ...

A Massachusetts man became the first person to try intranasal foralumab under an expanded access program for people with ...